Advanced search
Publication Cover
Current Medical Research and Opinion Volume 40, 2024 - Issue 4
Submit an article Journal homepage
76
Views
0
CrossRef citations to date
0
Altmetric
Rare Diseases

Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan

Yuichi Yoshidaa Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1114-7337View further author information
ORCID Icon,
Keiichi Tozawab AstraZeneca K.K, Osaka, JapanORCID Iconhttps://orcid.org/0000-0002-9351-0637View further author information
ORCID Icon,
Ryo Kotob AstraZeneca K.K, Osaka, JapanORCID Iconhttps://orcid.org/0000-0002-8403-0930View further author information
ORCID Icon,
Chikako Iwaob AstraZeneca K.K, Osaka, JapanORCID Iconhttps://orcid.org/0000-0002-7062-1828View further author information
ORCID Icon,
YongJin Kimc Evidera, Saint-Laurent, CanadaORCID Iconhttps://orcid.org/0000-0002-3055-9943View further author information
ORCID Icon,
Lu Band Evidera, PPD, Beijing, ChinaORCID Iconhttps://orcid.org/0000-0001-9388-9141View further author information
ORCID Icon &
Volkan Barute AstraZeneca, Cambridge, UKORCID Iconhttps://orcid.org/0000-0002-8734-2358View further author information
ORCID Icon show all
Pages 723-731 | Received 07 Nov 2023, Accepted 20 Feb 2024, Published online: 07 Mar 2024

References

  • Anderson JL, Gutmann DH. Neurofibromatosis type 1. Handb Clin Neurol. 2015;132:75–86. doi: 10.1016/B978-0-444-62702-5.00004-4.
  • Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834–843. doi: 10.1016/S1474-4422(14)70063-8.
  • Yoshida Y. Neurofibromatosis. In: Kelly AP, Taylor SC, editors. Taylor and Kelly’s dermatology for skin of color. 2nd ed. New York (NY): McGrawHill Press; 2016.
  • Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5(6):477–485. doi: 10.1634/theoncologist.5-6-477.
  • Niimura M. Neurofibromatosis in Japan. In: Ishibashi Y, Hori Y. editors. Tuberous sclerosis and neurofibromatosis:epidemiology, pathophysiology, biology and management. Amsterdam: Excerpta Medica. 1990. p. 22–31.
  • Ehara Y, Yamamoto O, Kosaki K, et al. Clinical severity in Japanese patients with neurofibromatosis 1 based on DNB classification. J Dermatol. 2017;44(11):1262–1267. doi: 10.1111/1346-8138.13902.
  • Fisher MJ, Blakeley JO, Weiss BD, et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 2022;24(11):1827–1844. doi: 10.1093/neuonc/noac146.
  • Weill Cornell Brain and Spine Center. Neurofibromatosis (NF1 and NF2). 2021. Available from: https://weillcornellbrainandspine.org/condition/neurofibromatosis-nf1-and-nf2/diagnosing-and-treating-neurofibromatosis.
  • Yang X, Desai K, Agrawal N, et al. Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a Medicaid population. Curr Med Res Opin. 2021; Jul37(9):1555–1561.
  • Yang X, Desai K, Agrawal N, et al. Treatment, resource use and costs among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas. Pediatric Health Med Ther. 2020;11:421–428. doi: 10.2147/PHMT.S265690.
  • Ogino M, Kawachi I, Otake K, et al. Current treatment status and medical cost for multiple sclerosis based on analysis of a Japanese claims database. Clin Exp Neuroimmunol. 2016;7(2):158–167. doi: 10.1111/cen3.12299.
  • Medical Data Vision. Overview of medical care database (as of the end of July 2018) actual number of patients 23.98 million 2018. 2021. Available from: https://www.mdv.co.jp/press/2018/detail_1028.html.
  • Komatsu N, Jun G, Yonezu T, et al. Real-world, retrospective study evaluating thromboembolic events, associated risk factors, and health-care resource utilization in Japanese patients with polycythemia vera. Int J Hematol. 2020;112(2):176–184. doi: 10.1007/s12185-020-02887-w.
  • Medical Data Vision. About MDV database. 2021. Available from: https://en.mdv.co.jp/about-mdv-database/.
  • Hirabaru K, Matsuo M. Neurological comorbidity in children with neurofibromatosis type 1. Pediatr Int. 2018;60(1):70–75. doi: 10.1111/ped.13388.
  • Koga M, Yoshida Y, Ehara Y, et al. Medical costs of surgical intervention for hospitalized patients with neurofibromatosis 1 in Japan. Eur J Dermatol. 2020;30(5):618–620. doi: 10.1684/ejd.2020.3869.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.